© 1989 by Oxford University Press
Journal of the National Cancer Institute, Vol. 81, No. 23, 1780-1786,
December 6, 1989
© 1989 Oxford University Press
Mutations in Human Breast Cancer: An Overview
Laboratory of Tumor Immunology and Biology, National Cancer Institute Bethesda, MD
Laboratory of Statistical and Mathematical Methodology, Division of Computer Research and Technology, National Institutes of Health Bethesda, MD
*Correspondence to: Robert Callahan, Ph.D., Laboratory of Tumor Immunology and Biology, Bldg. 10, Rm. 5B50, National Institutes of Health, Bethesda, MD 20892.
Studies of mammary tumorigenesis in mice infected with the mouse mammary tumor virus and in certain strains of transgenic mice with an activated oncogene have provided strong evidence that multiple mutations contribute to the initiation and progression of malignancies in the breast. The increasing availability of recombinant DNA probes that detect various proto-oncogenes, growth factor genes, and growth factor receptor genes, as well as restriction fragment length polymorphisms in the human population, have made possible a molecular approach for the identification of frequently occurring mutations in primary human breast tumor DNA. The aim of studies using this molecular approach has been to investigate whether specific mutations are highly associated with various clinical parameters, including disease prognosis. Eight mutations have been identified, including amplification of c-myc, c-erbB2, and int-2, as well as loss of heterozygosity on five chromosomes (1q, 3p, 11p, 13q, and 17p). Loss of heterozygosity is thought to unmask recessive mutations of tumor-suppressor genes. In some studies, amplification of either c-myc, c-erbB2, or int-2 has been found to have a significant association with high risk of relapse or poor survival. The current status of these mutations as potentially useful prognostic indicators for the management of the disease is controversial and points to the need for further research in this area. [J Natl Cancer Inst 81:1780–1786, 1989]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Plotnikov, Y. Li, T. H. Tran, W. Tang, J. P. Palazzo, H. Rui, and S. Y. Fuchs Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor Cancer Res., March 1, 2008; 68(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S C L Santos, L R Cavalli, I J Cavalli, R S Lima, B R Haddad, and E M S F Ribeiro Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil J. Clin. Pathol., April 1, 2004; 57(4): 374 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Glasow, L.-C. Horn, S. E. Taymans, C. A. Stratakis, P. A. Kelly, U. Kohler, J. Gillespie, B. K. Vonderhaar, and S. R. Bornstein Mutational Analysis of the PRL Receptor Gene in Human Breast Tumors with Differential PRL Receptor Protein Expression J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3826 - 3832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hirano, M. Emi, M. Tsuneizumi, Y. Utada, M. Yoshimoto, F. Kasumi, F. Akiyama, G. Sakamoto, S. Haga, T. Kajiwara, et al. Allelic Losses of Loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 Correlate with Postoperative Recurrence in Breast Cancer Clin. Cancer Res., April 1, 2001; 7(4): 876 - 882. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Sawey Role of Gap-Junctional Communication in Breast Cancer Progression and Chemoprevention J. Nutr., January 1, 2001; 131(1): 167S - 169. [Full Text]
|
|
|
|
|
|
Y. Utada, M. Emi, M. Yoshimoto, F. Kasumi, F. Akiyama, G. Sakamoto, S. Haga, T. Kajiwara, and Y. Nakamura Allelic Loss at 1p34-36 Predicts Poor Prognosis in Node-negative Breast Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3193 - 3198. [Abstract] [Full Text]
|
|
|
|
 |
|
 J Marx Many gene changes found in cancer Science, December 15, 1989; 246(4936): 1386 - 1388. [PDF]
|
|